Page 24 - Rivista SIMG 1 - Maggio 2023 - web

4. Chalasani N, et al. The diagnosis and 2021;340:35–43. 2013;10:666–675.
management of nonalcoholic fatty liver 8. Brouwers M, et al. Incidence of 12. Tapper EB, et al. The Performance
disease: Practice guidance from the type 2 diabetes in familial combined of Vibration Controlled Transient
American Association for the Study of Liver hyperlipidemia. BMJ Open Diabetes Res Elastography in a US Cohort of Patients
Diseases. Hepatology 2018;67:328-357. Care 2020;8:e001107. with Nonalcoholic Fatty Liver Disease. Am
5. Haflidadottir S, et al. Long-term follow- 9. Grant EG, et al. Carotid Artery Stenosis: J Gastroenterol 2016;111:677–684.
up and liver-related death rate in patients Grayscale and Doppler Ultrasound 13. Iqbal U, et al. The Epidemiology, Risk
with non-alcoholic and alcoholic related Diagnosis—Society of Radiologists in Profiling and Diagnostic Challenges
fatty liver disease. BMC Gastroenterol Ultrasound Consensus Conference. of Nonalcoholic Fatty Liver Disease.
2014;14:166. Ultrasound Q 2003;19:190–198. Medicines 2019;6:41.
6. Ekstedt M, et al. Long-term follow-up 10. Lee J-H, et al. Hepatic steatosis 14. Speliotes EK, et al. Fatty liver is
of patients with NAFLD and elevated liver index: A simple screening tool reflecting associated with dyslipidemia and
enzymes. Hepatology 2006;44:865-873. nonalcoholic fatty liver disease. Dig Liver dysglycemia independent of visceral fat:
7. Trinder M, et al. Polygenic architecture Dis 2010;42:503–508. The Framingham heart study. Hepatology
and cardiovascular risk of familial 11. Castera L, et al. Noninvasive evaluation 2010;51:1979–1987.
combined hyperlipidemia. Atherosclerosis of NAFLD. Nat Rev Gastroenterol Hepatol

Rivista Società Italiana di Medicina Generale n. 1 • 2023 23